

## REMARKS

Claims 1-3, 17-19, 21 and 25 will be pending following entry of this amendment. Claims 1 and 18 are amended. No new matter has been added.

### **Claim Rejections under 35 U.S.C. §103 (a)**

The Office Action rejects claims 1-3, 17-19, 21 and 25 under 35 U.S.C. §103 (a) as unpatentable in view of JP Abstract 401151514.

Claims 1-3, 17-36, 29 and 30 are rejected under 35 U.S.C. § 103(a) as allegedly being obvious over JP Abstract 401151514. The office action alleges that JP Abstract 401151514 teaches pyrogallol-4-carboxylic acid which it alleges falls within the scope of species of Formula A and B.

Both claims 1 and 18 have now been further amended to define 'X' substituents in subparagraph (b) as including alkylcarboxyls having four to twenty two carbons. Applicants respectfully submit that the instant claims, which are directed to methods of treating Alzheimer's disease now exclude gallic acid and pyrogallol-4-carboxylic acid. Additionally, Claim 1, which was previously amended to specifically exclude pyrogallol has been amended to delete "but excluding pyrogallol" as it would be redundant in light that the current amendment discussed above excludes this compound.

Applicant believes they have responded fully to all of the concerns expressed in the Office Action and respectfully requests reexamination of all rejected claims and early favorable action on them. If the Examiner has any further concerns, Applicant requests an immediate call to Rebecca Eagen at (425) 823-0400 x39.

Respectfully submitted,



Rebecca Eagen  
Reg. No. L0386

PROTEOTECH, INC.  
12040 115<sup>TH</sup> AVENUE N.E.  
KIRKLAND, WA 98034  
425-823-0400 x39